SCHEMBL22290643

SCHEMBL22290643

Cc1nccn1-c1cccc(B(O)O)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.53
CYP2E1 P05181 1/20 0.53
CYP2A6 P11509 1/20 0.53
ALDH1A1 P00352 2/20 0.43
MAOA P21397 1/20 0.42
MAOB P27338 1/20 0.42
ENPP2 Q13822 4/20 0.41
KDM4E B2RXH2 1/20 0.41
ICMT O60725 3/20 0.40
GRM5 P41594 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP19A1 P11511 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
F2 P00734 1/20 0.37
F10 P00742 1/20 0.37
ADH5 P11766 1/20 0.37
PDE4A P27815 1/20 0.36
PDE4B Q07343 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11929770 0.83 CYP3A4 (0.67) CYP3A4CYP2E1CYP2A6ALDH1A1MAOA
SCHEMBL30797803 0.79 CYP3A4 (0.57) CYP3A4CYP2E1CYP2A6ALDH1A1MAOA
SCHEMBL3507152 0.79 CYP3A4 (0.57) CYP3A4CYP2E1CYP2A6ALDH1A1MAOA
SCHEMBL17166601 0.78 CYP3A4 (0.61) CYP3A4CYP2E1CYP2A6ALDH1A1MAOA
SCHEMBL8695867 0.76 CYP3A4 (0.54) CYP3A4CYP2E1CYP2A6ALDH1A1MAOA
SCHEMBL22290749 0.76 CYP3A4 (0.57) CYP3A4CYP2E1CYP2A6ALDH1A1MAOA
SCHEMBL62408 0.76 CYP3A4 (0.57) CYP3A4CYP2E1CYP2A6ALDH1A1MAOA
SCHEMBL16923147 0.76 CYP3A4 (0.57) CYP3A4CYP2E1CYP2A6ALDH1A1MAOA
SCHEMBL11983591 0.76 CYP3A4 (0.57) CYP3A4CYP2E1CYP2A6ALDH1A1MAOA
SCHEMBL941596 0.74 ALDH1A1 (0.54) CYP3A4CYP2E1CYP2A6ALDH1A1MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3917527-B1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC (US) 2025-04-23 EP disclosed
CN-113645971-B Compounds and uses thereof 福宏治疗公司 2024-10-18 CN disclosed
US-20230079819-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-03-16 US disclosed
EP-3917527-A1 COMPOUNDS AND USES THEREOF Foghorn Therapeutics Inc. (US) 2021-12-08 EP disclosed
CN-113645971-A Compound and use thereof 福宏治疗公司 2021-11-12 CN disclosed
WO-2020160180-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2020-08-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230079819-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB CYP3A4 3718/4885CYP2E1 3701/4885CYP2A6 2405/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.